- Conditions
- Opioid Induced Constipation (OIC)
- Interventions
- placebo, NKTR-118
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 33
- States / cities
- Huntsville, Alabama • Pinson, Alabama • Tucson, Arizona + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 2,093
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme, GBM, Brain Cancer
- Interventions
- VAL-083 (Dianhydrogalactitol)
- Drug
- Lead sponsor
- Kintara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 5
- States / cities
- San Francisco, California • Denver, Colorado • Sarasota, Florida + 2 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen)
- Biological
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Miami, Florida • Boston, Massachusetts + 4 more
- Conditions
- Depression
- Interventions
- NSI-189 Phosphate, microcrystalline cellulose capsules
- Drug
- Lead sponsor
- Neuralstem Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Moderate to Severe Osteoarthritis
- Interventions
- SM04690, 0.03mg/2mL, SM04690, 0.07mg/2mL, SM04690, 0.23mg/2mL, Placebo
- Drug
- Lead sponsor
- Biosplice Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • El Cajon, California • Walnut Creek, California + 4 more
- Conditions
- Infections, Bacterial
- Interventions
- GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets, Placebo tablets, 13C-GSK1322322 stable isotope powder, GSK1322322 for injection, Placebo injection
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Multiple Myeloma
- Interventions
- Anti-KIR (1-7F9)
- Drug
- Lead sponsor
- Innate Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • New York, New York • Columbus, Ohio + 1 more
- Conditions
- Heart Failure, Congestive, Dilated Cardiomyopathy
- Interventions
- MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo Infusion, MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
- Genetic · Procedure
- Lead sponsor
- Celladon Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 22
- States / cities
- San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more
- Conditions
- Solid Tumors, Advanced Solid Tumors
- Interventions
- EP-100
- Drug
- Lead sponsor
- Esperance Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona
- Conditions
- Cancer
- Interventions
- SNX-5422
- Drug
- Lead sponsor
- Esanex Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Augusta, Georgia • Hackensack, New Jersey + 1 more
- Conditions
- Lymphocytic Leukemia, Chronic, SLL
- Interventions
- CAP-100
- Drug
- Lead sponsor
- Catapult Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Durham, North Carolina
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Interventions
- 90Y-AHN-12
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Attention-deficit Hyperactivity Disorder (ADHD)
- Interventions
- NFC-1
- Drug
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lassa Fever, Lassa Virus Infection
- Interventions
- rVSV∆G-LASV-GPC, Placebo/Diluent
- Drug · Other
- Lead sponsor
- International AIDS Vaccine Initiative
- Network
- Eligibility
- 18 Years to 51 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Honolulu, Hawaii • Brookline, Massachusetts
- Conditions
- Glioma
- Interventions
- BLZ-100
- Drug
- Lead sponsor
- Blaze Bioscience Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HIV Infections
- Interventions
- HIVAX, saline solution
- Biological
- Lead sponsor
- GeneCure Biotechnologies
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cancer
- Interventions
- PF-04691502
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Santa Monica, California • Detroit, Michigan + 2 more
- Conditions
- Solid Tumor
- Interventions
- ONO-7579
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- Lake Success, New York • New York, New York • Greenville, South Carolina + 1 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- TAK-648, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 2
- States / cities
- Anaheim, California • Chula Vista, California
- Conditions
- HIV Infections
- Interventions
- VRC-HIVADV014-00-VP
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2006
- U.S. locations
- 3
- States / cities
- San Francisco, California • Nashville, Tennessee • Seattle, Washington
- Conditions
- HIV Infections
- Interventions
- KP-1461
- Drug
- Lead sponsor
- Koronis Pharmaceuticals.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 9
- States / cities
- Bradenton, Florida • Miami, Florida • West Palm Beach, Florida + 6 more
- Conditions
- Necrotizing Enterocolitis
- Interventions
- IBP-9414, Placebo
- Drug
- Lead sponsor
- Infant Bacterial Therapeutics
- Industry
- Eligibility
- Up to 48 Hours
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 10 more
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- DE-104 medium concentration, DE-104 high concentration, Placebo, 0.005% latanoprost
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Artesia, California • Pasadena, California • San Francisco, California + 3 more
- Conditions
- Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
- Interventions
- ONCOS-102, Durvalumab, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- San Diego, California • Miami, Florida • Buffalo, New York + 3 more